Functional Neurosurgery Research Center, Shohada Tajrish Comprehensive Neurosurgical Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Auto-generated profile, based on publicly available information
Paria Shafiekhani
Functional Neurosurgery Research Center, Shohada Tajrish Comprehensive Neurosurgical Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Aim. Cardiotoxicity is a well-recognized complication of chemotherapy with Anthracyclines. However, results from trials evaluating beta-blockers for prevention are controversial. Therefore, we performed a meta-analysis to find whether prophylactic administration of beta-blockers can help prevent Anthracyclines-induced cardiotoxicity. Methods. We assessed randomized trials and observational studies where a prophylactic intervention was compared with a control arm in patients with a normal left ventricular ejection fraction (LVEF) receiving Anthracyclines. The primary outcome was EF reduction. The secondary outcome was the development of Cancer Therapeutics–Related Cardiac Dysfunction (CTRCD), defined as a decrease in the LVEF of >10% to a value of <53%. Results. We included 17 trials comprising 1291 patients (671 patients in the intervention arm and 620 in the control arm). Carvedilol was administered in eight studies, and others used bisoprolol, metoprolol, or nebivolol. Compared with baseline, LVEF reduced in both intervention and control groups after chemotherapy ( , 95% CI: -2.94, -0.92, , vs. , 95% CI: -6.51, -3.04, , , respectively). LVEF was less reduced among the beta-blocker receivers ( , 95% CI: 1.41–5.46, , ). Among the eight studies reporting the incidence of CTRCD, 45 out of 370 participants in the intervention arm and 54 out of 341 in the control arm were reported to experience this complication ( ; 95% CI: 0.53,1.09; ; ). Conclusion. Treatment with beta-blockers prevents dilatation of the left ventricle, development of diastolic dysfunction, and reduction of LVEF. However, these hemodynamic effects do not translate into a significant reduction in CTRCD incidence and prevention of hospitalization for heart failure or cardiac death.
: An emerging area of computer science is artificial intelligence (AI), which involves creating machines capable of learning, reasoning, and solving problems in the same way as humans. There is increasing use of machine learning techniques in the medical field, along with image recognition, language processing, and data mining, ranging from automated image analysis to disease prediction. Neurosurgery is frequently regarded as a pioneer in developing disruptive and innovative technologies that have significantly altered the course of acute and chronic disorders, such as epilepsy and brain tumors. Artificial intelligence platforms have been developed in recent decades to contribute to the paradigm shift in brain tumor surgery. Artificial intelligence platforms can result in safer and more effective brain tumor surgery. Artificial intelligence will soon be used to evaluate, analyze, and provide high-quality medical care. Robots will also become more prevalent in neurosurgery. Hence, physicians must keep up with this revolution to personalize patient care and deliver meaningful outcomes. For neurosurgeons to continue providing high-quality care in the future, they must understand artificial intelligence and utilize it effectively.